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The majority of studies indicated that 
elevated levels of established cardiovascular risk 
factors, such as age, sex, total cholesterol, LDL 
cholesterol, systolic blood pressure, body mass 
index, and a decrease in HDL cholesterol, are 
associated with an increased CIMT in a graded 
manner. 
Hypertension is an important risk factor for 
cardiovascular complications, especially stroke.[1] 
Hypertension also has an important complex role in 
the pathogenesis of atherosclerosis. A continual 
elevated in blood pressure caused changes in 
vascular endothelial function, such as increased 
vascular permeability, decreased endothelial 
vasodilators, and increased adherence of 
leukocytes on the surface of the endothelium to the 
accumulation of macrophages in the intima layer.[2] 
Hypertension also increases vascular smooth 
muscle cell (VSMC) proliferation. On the other 
hand, inflammation and endothelial dysfunction 
also play a critical role in the pathogenesis of 
hypertension.[3] Isolated systolic hypertension with 
elevated pulse pressure is an indication of blood 
vessel stiffness, that can be considered as a marker 
of atherosclerosis. Several studies have shown a 
correlation between hypertension and CIMT 
thickness and blood vessel stiffness. [4] [5] 
Is the increase in CIMT related to an increase in CVD 
events? 
Based on many studies, both cross 
sectional and longitudinal, it has been proven 
that carotid intima-media thickness (CIMT) 
predicts cardiovascular events (CVD) and well- 
described surrogate marker for cardiovascular 
risk. According to review by Yokoyama et al., a 
thickened CIMT correlates with the presence of 
myocardial infarction and stroke by cross- 
sectional analysis. Several prospective studies 
have shown an association between increased 
CIMT and the incidence of cardiovascular 
disease in the general population with or 
without prior cardiovascular disease. CIMT is 
significantly higher in diabetic patients than in 
nondiabetic subjects, and an increased CIMT is 
associated with angiography-evaluated 
coronary artery disease and predicts future 
events of silent brain infarction and coronary 
heart disease in type 2 diabetic subjects.[6] 
Can antihypertensive drugs reduce the thickness 
of the CIMT? 
Hypertension has been associated with 
atherosclerosis and cardiovascular disease. 
Carotid intima media thickness is increased in 
hypertensive patients. But, the correlation 
between carotid intima media thickness and 
antihypertensive agents is still uncertain. 
An observational cohort study of 1809 
patients showed that 1079 hypertensive 
patients had a thicker CIMT that was thicker 
than non-hypertensive patients, with CIMT of 
(0.72 ± 17 mm    vs    0.64 ± 15 mm, P < .001), 
(0.31 ± 0.07 mm vs 0.30 ± 0.06 mm, P <.001), 
and (0.41 ± 0.13 mm    vs     0.35 ± 0.12 mm, P < 
.001). Additionally, hypertensive patients on 
beta‐blockers also had thicker CIMT than the 
non‐beta‐blocker group, with CIMT of 
Clinical and Research Journal in Internal Medicine 
Vol. 01 No. 1, May 2020 
e-ISSN: 2723 - 5122, p-ISSN: 2723 - 5130 
Available online at https://crjim.ub.ac.id/index.php/crjim/ 





(0.74 ± 0.18 mm vs 0.71 ± 0.16 mm, p = 0.018), 
(0.33 ± 0.09 mm vs 0.31 ± 0.07 mm, 
p= 0.029), and (0.43 ± 0.13 mm vs 
0.40 ± 0.13 mm, p = 0.035). Multivariate analysis 
showed that CIMT was only correlated with beta‐ 
blockers (OR= 2.489, CI = 1.183‐5.239, p=0.016). 
This study showed that beta‐blocker could be 
associated with increased carotid wall thickness as 
well. [7] 
Other study showed that enalapril (10 
mg/d), reduced CIMT thickening by 0.01 mm/y. 
Half of the patients in this 2-year follow-up study 
had antihypertensive agents at baseline, and 
additional treatment with enalapril did not lower 
systemic blood pressure levels; therefore, the 
reduction of CIMT appeared independent of a blood 
pressure–lowering effect.[8] This is likely because of 
their anti-inflammatory effect of ACE-inhibitor by 
suppressing generation of reactive oxygen species 
in humans.[9] 
Results study by Tantri NL et al., one of the 
articles in the current edition, showed that there 
was a significant difference in CIMT between 
control group and therapy group (ACE-I or CCB), 
and treatment with amlodipine (CCB) showed the 
lowest CIMT but not significantly different 
compared to the ACE-I therapy group (0.69±0.02 
vs 0.86 ± 0.06, p=0.879). Meta-analysis of 5 trials 
with a total of 287 patients comparing ACE 
inhibitors with CCBs. Mean IMT at baseline ranged 
from 702 to 1038 μm. Compared with ACE 
inhibitors, CCBs significantly reduced the yearly 
increased in carotid IMT by 23 μm (95% CI: −42 to 
−4; p = 0.02). CCB seems having more impact on 
CIMT regression, possibly related to the effects of 
amlodipine on vascular smooth muscle 
proliferation, as research conducted by Lai et al. on 
VSMC culture in hypertensive rats. Amlodipine can 
inhibit DNA synthesis and VSMC proliferation by 
evaluating the growth factor expression impact, 
phenotype changes, and vascular smooth muscle 
cell (VSMC) proliferation in hypertensive rats. 
Amlodipine can inhibit the expression of PDGF, 
TGF-β1, and basic FGF, also mRNAs in VSMCs of 
hypertensive rats. Amlodipine inhibits the marker 
expression of osteopontin synthesis phenotypes 
and Gla mRNAs matrix, which shows the process of 
inhibiting VSMC growth and changing contractile 
phenotypes into synthetic phenotypes.[10] Based on 
the research results of Lai et al, it can be assumed 
that the antiproliferative effect of amlodipine is not 
associated with a decrease in blood pressure. 
Is CIMT regression associated with a reduction in 
cardiovascular events? 
It is well known that there is a positive 
correlation between CIMT and CVD events. 
Increased carotid IMT is associated with an 
increased risk of coronary heart disease (CHD) 
and cerebrovascular events (CBV). There are 
still questions, does the favorable changes of 
IMT reflect prognostic benefits or have clinical 
usefulness? what are the changes in CIMT that 
result from therapies correlate with nonfatal 
myocardial infarction (MI)? 
Information regarding the potential of 
regression (or diminished progression) of 
CIMT for reduction of cardiovascular events is 
still limited. In a meta‐regression analysis of 
15.598 patients, it was documented that 
regression in CIMT progress between active‐ 
treatment (antihypertensive, antidiabetic, or 
lipid‐lowering) and placebo groups was 
associated with a greater risk of myocardial 
infarction in the placebo‐arm. Specifically, 
every 0.01 mm/y regression in CIMT features a 
lower risk of myocardial infarction (odds ratio 
[OR]: 0.82; 95% CI: 0.69 to 0.96).[11] 
On the other hand, based on another 
meta-regression analysis of 41 involving 
18,307 participants, it was concluded that there 
was no significant relationship between IMT 
regression and CHD events (Tau 0.91, p = 0.37), 
CBV events (Tau -0.32, p = 0.75), and all- cause 
death (Tau -0.41, p = 0.69). In addition, 
subjects' baseline characteristics, 
cardiovascular risk profile, IMT at baseline, 
follow-up, and quality of the trials did not 
significantly influence the association between 
IMT changes and clinical outcomes. regression 
or slowed progression of carotid IMT, induced 
by cardiovascular drug therapies, do not reflect 
reduction in cardiovascular events.[12] 
Another study involved 14 population- 
based cohorts with 45,828 individuals. During 
a median follow-up of 11 years, 4007 first-time 
MIs or strokes occurred. Refitted the risk 
factors of the Framingham Risk Score and then 
extended the model with common CIMT 
measurements to estimate the absolute 10- 
year risks to develop a first-time MI or stroke in 
both models. The C statistic of both models was 





similar (0.757; 95% CI, 0.749-0.764; and 0.759; 
95% CI, 0.752-0.766). The net reclassification 
improvement with the addition of common 
CIMT was small (0.8%; 95% CI, 0.1%- 
1.6%). In those at intermediate risk, the net 
reclassification improvement was 3.6% in all 
individuals (95% CI, 2.7%-4.6%) and no 
differences between men and women. It was 
concluded that the addition of common CIMT 
measurements to the Framingham Risk Score was 
associated with small improvement in 10-year risk 
prediction of first-time myocardial infarction or 
stroke, but this improvement is unlikely to be of 
clinical importance.[13] 
More recent study in 31 cohort studies with 
2 CIMT scans (total n = 89070) on average 3.6 
years apart and clinical follow-up, sub-cohorts 
were drawn: (A) individuals with at least 3 
cardiovascular risk factors without previous CVD 
events, (B) individuals with carotid plaques 
without previous CVD events, and (C) individuals 
with previous CVD events. There are endpoint 
events in groups A, B and C, which are 3483, 2845 
and 1165, respectively. Average common CIMT was 
0.79mm ± 0.16mm, and annual common CIMT 
change was 0.01mm ± 0.07mm, both in group A. 
The pooled HR per SD of annual common CIMT 
change (0.02 to 0.43mm) was 0.99 (95% CI: 0.95– 
1.02) in group A, 0.98 (0.93–1.04) in group B, and 
0.95 (0.89–1.04) in group C. The HR per SD of 
common CIMT (average of the first and the second 
CIMT scan, 0.09 to 0.75mm) was 1.15 (1.07–1.23) 
in group A, 1.13 (1.05–1.22) in group B, and 1.12 
(1.05–1.20) in group C. It was concluded that CIMT 
change does not relate to future risk events in high- 
risk individuals.[14] 
Several hypotheses have been suggested to 
explain this discrepancy. One credible argument is 
that the small CIMT change, assessed with 
reasonable to considerable measurement error in 
cohort studies, and the low event risk in the 
asymptomatic general population make it difficult 
to discern such association.[15] 
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